Literature DB >> 17632455

Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues.

Jiangling J Tu1, Stephen Rohan, Jean Kao, Naoki Kitabayashi, Susan Mathew, Yao-Tseng Chen.   

Abstract

Recurrent gene fusions between TMPRSS2 and ETS family genes have recently been shown to occur at a high frequency in prostate cancer. In this study, we used formalin-fixed paraffin-embedded tissue and evaluated both TMPRSS2-ERG and TMPRSS2-ETV1 fusions by reverse transcription polymerase chain reaction (RT-PCR) and fluorescence in situ hybridization (FISH). The results were correlated to overexpression of the downstream ERG and ETV1 sequences. Of 82 cases examined, TMPRSS2-ETV1 fusion was seen in only one case, by FISH. In comparison, TMPRSS2-ERG fusion was documented in 35 cases (43%) by either RT-PCR or FISH. Deletion, rather than translocation, was found to be the main mechanism for TMPRSS2-ERG gene fusion (81 vs 19%). RT-PCR and FISH results correlated well, with most positive cases resulting in overexpression of downstream ERG sequences. Several TMPRSS2-ERG fusion transcript variants were identified, most of which are predicted to encode truncated ERG proteins. Prostate cancer of Gleason's scores 6 or 7 had more frequent TMPRSS2-ERG fusions than higher-grade tumors, but this difference was not statistically significant (P=0.42). On the other hand, mucin-positive carcinomas more often harbor such gene fusions when compared to mucin-negative tumors (P=0.004). These morphological correlates, and more importantly the potential correlation of such fusions to clinical outcome and treatment responses, should be further explored.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17632455     DOI: 10.1038/modpathol.3800903

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  64 in total

1.  A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.

Authors:  Bo Han; Rohit Mehra; Saravana M Dhanasekaran; Jindan Yu; Anjana Menon; Robert J Lonigro; Xiaosong Wang; Yusong Gong; Lei Wang; Sunita Shankar; Bharathi Laxman; Rajal B Shah; Sooryanarayana Varambally; Nallasivam Palanisamy; Scott A Tomlins; Chandan Kumar-Sinha; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

2.  High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.

Authors:  Adrian Box; Mohammed Alshalalfa; Samar A Hegazy; Bryan Donnelly; Tarek A Bismar
Journal:  Tumour Biol       Date:  2016-06-07

Review 3.  Recurrent rearrangements in prostate cancer: causes and therapeutic potential.

Authors:  Nicole M White; Felix Y Feng; Christopher A Maher
Journal:  Curr Drug Targets       Date:  2013-04       Impact factor: 3.465

4.  Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer.

Authors:  Said Rahim; Aykut Uren
Journal:  Am J Transl Res       Date:  2013-04-19       Impact factor: 4.060

5.  Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.

Authors:  Alcides Chaux; Roula Albadine; Antoun Toubaji; Jessica Hicks; Alan Meeker; Elizabeth A Platz; Angelo M De Marzo; George J Netto
Journal:  Am J Surg Pathol       Date:  2011-07       Impact factor: 6.394

Review 6.  Recurrent gene fusions in prostate cancer.

Authors:  Chandan Kumar-Sinha; Scott A Tomlins; Arul M Chinnaiyan
Journal:  Nat Rev Cancer       Date:  2008-06-19       Impact factor: 60.716

7.  ETS gene fusions and prostate cancer.

Authors:  Wei Huang; Michelle Waknitz
Journal:  Am J Transl Res       Date:  2009-05-25       Impact factor: 4.060

8.  ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.

Authors:  J R Gsponer; M Braun; V J Scheble; T Zellweger; A Bachmann; S Perner; T Vlajnic; M Srivastava; S H Tan; A Dobi; I A Sesterhenn; S Srivastava; L Bubendorf; C Ruiz
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-01-28       Impact factor: 5.554

9.  ETS rearrangements and prostate cancer initiation.

Authors:  Brett S Carver; Jennifer Tran; Zhenbang Chen; Arkaitz Carracedo-Perez; Andrea Alimonti; Caterina Nardella; Anuradha Gopalan; Peter T Scardino; Carlos Cordon-Cardo; William Gerald; Pier Paolo Pandolfi
Journal:  Nature       Date:  2009-02-12       Impact factor: 49.962

10.  Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts.

Authors:  B G Barwick; M Abramovitz; M Kodani; C S Moreno; R Nam; W Tang; M Bouzyk; A Seth; B Leyland-Jones
Journal:  Br J Cancer       Date:  2010-01-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.